{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T07:57:56Z","timestamp":1757577476984},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1016\/j.jhep.2010.03.006","type":"journal-article","created":{"date-parts":[[2010,4,19]],"date-time":"2010-04-19T08:57:14Z","timestamp":1271667434000},"page":"261-266","source":"Crossref","is-referenced-by-count":32,"title":["Clinical, biochemical, and pathological characteristics of clevudine-associated myopathy"],"prefix":"10.1016","volume":"53","author":[{"given":"Won Young","family":"Tak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo Young","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang Min","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min Kyu","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seong Woo","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Oh","family":"Kweon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Young","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoon Kyung","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2010.03.006_bib1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2893.2003.00487.x","article-title":"Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures","volume":"11","author":"Lavanchy","year":"2004","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2010.03.006_bib2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1365-2036.2008.03731.x","article-title":"Review article: current antiviral therapy of chronic hepatitis B","volume":"28","author":"Ayoub","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2010.03.006_bib3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.7326\/0003-4819-150-2-200901200-00101","article-title":"Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference","volume":"150","author":"Shamliyan","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2010.03.006_bib4","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1128\/AAC.45.9.2495-2501.2001","article-title":"In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (\u2212)-beta-D-2,6-diaminopurine dioxolane and 2\u2032-fluoro-5-methyl-beta-L-arabinofuranosyluracil","volume":"45","author":"Chin","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2010.03.006_bib5","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1128\/AAC.39.4.979","article-title":"Use of 2\u2032-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein\u2013Barr virus","volume":"39","author":"Chu","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2010.03.006_bib6","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/0006-2952(96)00049-4","article-title":"Inhibition of Epstein\u2013Barr virus replication by a novel L-nucleoside, 2\u2032-fluoro-5-methyl-beta-L-arabinofuranosyluracil","volume":"51","author":"Yao","year":"1996","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jhep.2010.03.006_bib7","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1128\/AAC.40.2.380","article-title":"Inhibition of hepatitis B virus by a novel L-nucleoside, 2\u2032-fluoro-5-methyl-beta-L-arabinofuranosyl uracil","volume":"40","author":"Balakrishna Pai","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2010.03.006_bib8","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1021\/jm960098l","article-title":"Structure\u2013activity relationships of 1-(2-deoxy-2-fluoro-beta-L-arabinofuranosyl)pyrimidine nucleosides as anti-hepatitis B virus agents","volume":"39","author":"Ma","year":"1996","journal-title":"J Med Chem"},{"issue":"Suppl. 3","key":"10.1016\/j.jhep.2010.03.006_bib9","first-page":"113","article-title":"Preclinical investigation of L-FMAU as an anti-hepatitis B virus agent","volume":"3","author":"Chu","year":"1998","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2010.03.006_bib10","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1002\/hep.21629","article-title":"Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B","volume":"45","author":"Yoo","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2010.03.006_bib11","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/hep.21800","article-title":"Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression","volume":"46","author":"Yoo","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2010.03.006_bib12","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/j.1872-034X.2009.00515.x","article-title":"Mitochondrial myopathy caused by clevudine therapy in chronic hepatitis B patients","volume":"39","author":"Tak","year":"2009","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2010.03.006_bib13","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1002\/hep.22959","article-title":"Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA","volume":"49","author":"Seok","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2010.03.006_bib14","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2009.04.019","article-title":"Clevudine myopathy in patients with chronic hepatitis B","volume":"51","author":"Kim","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2010.03.006_bib15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jhep.2008.10.001","article-title":"EASL Clinical Practice Guidelines: management of chronic hepatitis B","volume":"50","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2010.03.006_bib16","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2010.03.006_bib17","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1097\/00000478-199512000-00007","article-title":"Chronic hepatitis. An update on terminology and reporting","volume":"19","author":"Batts","year":"1995","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jhep.2010.03.006_bib18","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1212\/01.wnl.0000257819.47628.41","article-title":"Construction and validation of a quality of life questionnaire for neuromuscular disease (INQoL)","volume":"68","author":"Vincent","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.jhep.2010.03.006_bib19","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/ageing\/29.3.223","article-title":"Reliability of measurements of muscle tone and muscle power in stroke patients","volume":"29","author":"Gregson","year":"2000","journal-title":"Age Ageing"},{"key":"10.1016\/j.jhep.2010.03.006_bib20","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJM199510263331702","article-title":"Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B","volume":"333","author":"McKenzie","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2010.03.006_bib21","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/hep.21166","article-title":"A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B","volume":"43","author":"Lee","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2010.03.006_bib22","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S1567-7249(02)00003-X","article-title":"Mitochondrial dysfunction and antiretroviral nucleoside analog toxicities: what is the evidence?","volume":"1","author":"Dagan","year":"2002","journal-title":"Mitochondrion"},{"key":"10.1016\/j.jhep.2010.03.006_bib23","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1128\/AAC.49.5.2044-2049.2005","article-title":"Behavior of thymidylate kinase toward monophosphate metabolites and its role in the metabolism of 1-(2\u2032-deoxy-2\u2032-fluoro-beta-L-arabinofuranosyl)-5-methyluracil (Clevudine) and 2\u2032,3\u2032-didehydro-2\u2032,3\u2032-dideoxythymidine in cells","volume":"49","author":"Hu","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2010.03.006_bib24","doi-asserted-by":"crossref","first-page":"5453","DOI":"10.1074\/jbc.M109025200","article-title":"Phosphorylation of pyrimidine deoxynucleoside analog diphosphates: selective phosphorylation of L-nucleoside analog diphosphates by 3-phosphoglycerate kinase","volume":"277","author":"Krishnan","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2010.03.006_bib25","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1128\/AAC.42.4.833","article-title":"Unique metabolism of a novel antiviral L-nucleoside analog, 2\u2032-fluoro-5-methyl-beta-L-arabinofuranosyluracil: a substrate for both thymidine kinase and deoxycytidine kinase","volume":"42","author":"Liu","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2010.03.006_bib26","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1007\/s00259-008-0738-9","article-title":"Tracking cellular stress with labeled FMAU reflects changes in mitochondrial TK2","volume":"35","author":"Tehrani","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.jhep.2010.03.006_bib27","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1111\/j.1365-2036.2008.03686.x","article-title":"Clinical trial: a phase II, randomized study evaluating the safety, pharmacokinetics and anti-viral activity of clevudine for 12 weeks in patients with chronic hepatitis B","volume":"27","author":"Lim","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2010.03.006_bib28","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/hep.20257","article-title":"A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B","volume":"40","author":"Marcellin","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2010.03.006_bib29","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1177\/135965350901400401","article-title":"Clinical and virological responses to clevudine therapy in chronic hepatitis B patients: results at 1 year of an open-labelled prospective study","volume":"14","author":"Ko","year":"2009","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2010.03.006_bib30","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.3748\/wjg.14.3549","article-title":"Clinical features of adverse reactions associated with telbivudine","volume":"14","author":"Zhang","year":"2008","journal-title":"World J Gastroenterol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827810002692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827810002692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T21:03:28Z","timestamp":1685567008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827810002692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S0168827810002692"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2010.03.006","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}